Tokai Pharma (TKAI) Misses Q1 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. AXP
9. ZETA
10. DAL

Go back to Tokai Pharma (TKAI) Misses Q1 EPS by 1c

Tokai Pharmaceuticals Reports First Quarter 2016 Financial Results

May 10, 2016 7:15 AM EDT

BOSTON--(BUSINESS WIRE)-- Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today reported company highlights and financial results for the quarter ended March 31, 2016.

Over the past quarter we have made significant progress in our clinical development program for galeterone, as we continued to accelerate screening and enrollment in our ARMOR3-SV trial and expanded our Phase 2 trial to include additional mCRPC patients who have acquired resistance to enzalutamide, said Jodie Morrison, President and Chief Executive Officer of Tokai. We... More